These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34328594)

  • 1. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.
    Yahi N; Di Scala C; Chahinian H; Fantini J
    Glycoconj J; 2022 Feb; 39(1):1-11. PubMed ID: 34328594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer's Disease Therapy.
    Azzaz F; Chahinian H; Yahi N; Fantini J; Di Scala C
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy Strategy for Alzheimer's and Parkinson's Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells.
    El-Battari A; Rodriguez L; Chahinian H; Delézay O; Fantini J; Yahi N; Di Scala C
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
    Di Scala C; Yahi N; Flores A; Boutemeur S; Kourdougli N; Chahinian H; Fantini J
    Biochim Biophys Acta; 2016 Feb; 1862(2):213-22. PubMed ID: 26655601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?
    Fantini J; Chahinian H; Yahi N
    Protein Sci; 2020 Aug; 29(8):1748-1759. PubMed ID: 32567070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery.
    Di Scala C; Armstrong N; Chahinian H; Chabrière E; Fantini J; Yahi N
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular α-synuclein drives sphingosine 1-phosphate receptor subtype 1 out of lipid rafts, leading to impaired inhibitory G-protein signaling.
    Badawy SMM; Okada T; Kajimoto T; Hirase M; Matovelo SA; Nakamura S; Yoshida D; Ijuin T; Nakamura SI
    J Biol Chem; 2018 May; 293(21):8208-8216. PubMed ID: 29632069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gangliosides, α-Synuclein, and Parkinson's Disease.
    Ledeen RW; Wu G
    Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of α-Synuclein Oligomers in Parkinson's Disease.
    Du XY; Xie XX; Liu RT
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
    Limegrover CS; Yurko R; Izzo NJ; LaBarbera KM; Rehak C; Look G; Rishton G; Safferstein H; Catalano SM
    J Neurosci Res; 2021 Apr; 99(4):1161-1176. PubMed ID: 33480104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein.
    Di Scala C; Yahi N; Boutemeur S; Flores A; Rodriguez L; Chahinian H; Fantini J
    Sci Rep; 2016 Jun; 6():28781. PubMed ID: 27352802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding peptide.
    Yahi N; Fantini J
    PLoS One; 2014; 9(8):e104751. PubMed ID: 25140899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson.
    Zabrocki P; Bastiaens I; Delay C; Bammens T; Ghillebert R; Pellens K; De Virgilio C; Van Leuven F; Winderickx J
    Biochim Biophys Acta; 2008 Oct; 1783(10):1767-80. PubMed ID: 18634833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron-mediated interaction of alpha synuclein with lipid raft model membranes.
    Perissinotto F; Stani C; De Cecco E; Vaccari L; Rondelli V; Posocco P; Parisse P; Scaini D; Legname G; Casalis L
    Nanoscale; 2020 Apr; 12(14):7631-7640. PubMed ID: 32104855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of α-synuclein oligomers with lipid membranes.
    Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
    Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.